Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Postherpetic neuralgia Stories

2010-11-03 06:30:00

SAN MATEO, Calif., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Recent Highlights: Qutenza user base expands by 172 % Astellas advances E.U. launch and post-marketing studies NGX-1998 Phase 2 clinical trial initiated in PHN patients Upcoming Qutenza® Milestones: Qutenza specific J-Code expected to be effective in January 2011 sNDA submission in HIV-associated neuropathy to FDA in 1H 2011 NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing...

2010-11-02 08:00:00

SAN MATEO, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced dosing of the first patient in its Phase 2 clinical study of NGX-1998, a liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN). The target profile for NGX-1998 is to provide safety, efficacy and tolerability that is at least comparable to...

2010-10-28 16:37:00

NEW YORK, Oct. 28 /PRNewswire-FirstCall/ -- Pfizer Inc.(NYSE: PFE) announced today that the Japanese Ministry of Health, Labour and Welfare approved Lyrica® (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment of postherpetic neuralgia on April 16, 2010. Lyrica is the first medication approved for peripheral neuropathic pain in Japan where it is co-promoted with Eisai Co., Ltd....

2010-10-28 08:00:00

SAN MATEO, Calif., Oct. 28 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 21st Annual Oppenheimer & Co Healthcare Conference, to be held November 2-3, 2010 at the Waldorf-Astoria in New York, NY. Mr. DiTonno and Stephen Ghiglieri, Executive Vice President, Chief Operating...

2010-10-28 07:30:00

SAN MATEO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Wednesday, November 3, 2010 at 8:30 a.m. EDT (5:30 a.m. PDT) to report results for its third quarter ended September 30, 2010. The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Executive...

2010-10-18 08:00:00

SAN MATEO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP)). Following a recent meeting with the U.S. Food and Drug...

2010-10-06 07:00:00

BURLINGTON, Mass., Oct. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, although NeurogesX/Astellas's Qutenza is only approved for postherpetic neuralgia, surveyed U.S. physicians are likely to prescribe the drug for all neuropathic pain types. When asked to assume that patients suffering from other forms of neuropathic pain would be reimbursed for the cost of Qutenza treatment, 43 percent of...

2010-10-04 22:50:25

Multicenter study looks at impact for prevention strategies Acute herpes zoster, or shingles, interferes with all health areas for people with the condition, including sleep, enjoyment of life and general activities, according to a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj091711.pdf. Herpes zoster is a reactivation of the chicken pox (varicella-zoster) virus which results in pain and a rash with small blisters. It...

2010-09-16 07:00:00

BALTIMORE, Md., Sept. 16 /PRNewswire/ --The American Pain Foundation (APF), in partnership with professional baseball player LaTroy Hawkins, acknowledges those suffering from Postherpetic Neuralgia (PHN) today, as it recognizes the second annual PHN Awareness Day. PHN Awareness Day was created to raise awareness to the pain caused by shingles and PHN, also known as after-shingles pain. Shingles is caused by the reactivation of the same virus that causes chickenpox and can affect an...

2010-09-07 15:00:00

SAN MATEO, Calif., Sept. 7 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at three upcoming conferences: the Rodman & Renshaw Global Investment Conference, to be held September 13-15, 2010 in New York, NY; the UBS Global Life Sciences Conference, taking place September 20-22, 2010 in...


Latest Postherpetic neuralgia Reference Libraries

69_7b87211f9314eacab994d465558a3a1b
2011-01-24 12:56:26

Herpes zoster (or zoster), is known as shingles or zona and is a viral disease characterized by painful skin rash with blisters in a limited area on one side of the body. Initial infection causes chickenpox. Once chickenpox is over the virus remains in the body and can cause shingles. It can become latent in the nerve cell bodies and sometimes in the dorsal root, cranial nerve, or autonomic ganglion. Years after initial infection, another breakout can cause a painful rash. The rash usually...

More Articles (1 articles) »